0001720893 2026-03-27 2026-03-27 0001720893 1 2026-03-27 2026-03-27 0001720893 2 2026-03-27 2026-03-27 0001720893 3 2026-03-27 2026-03-27 iso4217:USD pure shares S-8 S-8 EX-FILING FEES 0001720893 BioXcel Therapeutics, Inc. N/A false false false S-8 BioXcel Therapeutics, Inc. Equity Common stock, $0.001 par value per share, 2020 Incentive Award Plan true 119000 2.01 239190.00 0.0001381 33.03 Equity Common stock, $0.001 par value per share, 2020 Incentive Award Plan true 774110 1.435 1110847.85 0.0001381 153.41 Equity Common stock, $0.001 par value per share, 2020 Employee Stock Purchase Plan true 223277 1.435 320402.49 0.0001381 44.25 1670440.34 230.69 0.00 230.69 (a) In accordance with Rule 416(b) under the Securities Act of 1933, as amended (the "Securities Act"), the shares of common stock, par value $0.001 per share (the "Common Stock"), of BioXcel Therapeutics, Inc. (the "Registrant") being registered hereunder include such indeterminate number of shares of the Common Stock as may be issuable with respect to the shares of the Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions. (b) Consists of 893,110 shares of the Registrant's Common Stock that were automatically added to the shares authorized for issuance under the Company's 2020 Incentive Award Plan (as amended, the "2020 Plan") on January 1, 2026 pursuant to an "evergreen" provision contained in the 2020 Plan, of which 119,000 shares were issued upon the exercise of stock options at a weighted average exercise price of $2.01 per share. See Note 1(a) (a) Consists of shares reserved for future issuance under the 2020 Plan. (b) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based $1.435 per share, which represents the average of the high and low prices of the Registrant's Common Stock on March 24, 2026 as reported on The Nasdaq Capital Market. See Note 1(a) and 2(b) (a) Consists of 223,277 shares of the Registrant's Common Stock that were automatically added to the shares authorized for issuance under the Company's 2020 Employee Stock Purchase Plan (as amended, the "2020 ESPP") on January 1, 2026 pursuant to an "evergreen" provision contained in the 2020 ESPP.